Currently, sotorasib and adagrasib are recommended by the National Comprehensive Cancer Network (NCCN) guidelines as a subsequent treatment option for patients with KRAS G12C-mutant NSCLC in second-line or beyond, if no previous KRAS G12C-targeted therapy was given (30). Here, KRAS is linked to non-small cell lung carcinoma.